CCM
SLNO

Catalio Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Catalio Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$6.5M – 47
2025
Q1 		$6.5M Buy
+100,000
New +$4.87M 1.58% 18

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Catalio Capital Management's SLNO Position: Q1 2026 in Review

Catalio Capital Management increased its Soleno Therapeutics (SLNO) stake by 60% in Q1 2026, buying an estimated $8.53M and bringing the position to 577,808 shares worth $19.3M. The position accounts for 4.04% of the portfolio, ranked #9.

Catalio Capital Management first reported a position in SLNO in Q1 2025 and has held it in 5 quarters since. The position peaked at $34.3M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Catalio Capital Management held 577,808 shares of Soleno Therapeutics worth $19.3M as of Q1 2026.
  • Catalio Capital Management bought 217,468 Soleno Therapeutics shares in Q1 2026, an estimated $8.53M.
  • Soleno Therapeutics made up 4.04% of Catalio Capital Management's portfolio in Q1 2026, its #9 holding.
  • Catalio Capital Management first reported a position in Soleno Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Catalio Capital Management's Soleno Therapeutics position peaked at $34.3M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.